5-Hydroxy-ω-N-isopropyl-tryptamin | 92032-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Hydroxy-ω-N-isopropyl-tryptamin
• 英文别名: 3-(2-isopropylamino-ethyl)-indol-5-ol；5-hydroxy-N-isopropyltryptamine；3-[2-(propan-2-ylamino)ethyl]-1H-indol-5-ol
• CAS: 92032-49-0
• 化学式: C₁₃H₁₈N₂O
• 分子量: 218.299
• InChiKey: CQGBZOIVCUQVSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018029545A1

  公开（公告）日：2018-02-15

  The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

  本公开提供化合物的公式I、公式II、公式III、公式IV、公式V、公式VI、公式VII、公式VIII、公式IX、公式X、公式XI、公式XII、公式XIII、公式XIV和公式XV，或其药用可接受盐，以及其多型、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以制成口服、栓剂、经皮、颊部、直肠、局部、经皮、经粘膜、静脉、全身、糖浆或注射用药物。这些组合物可用于治疗肠易激综合征（IBS）、炎症性肠病或其相关并发症。
• [EN] MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING<br/>[FR] CONJUGUÉS CHÉLATÉS À BASE DE MANGANÈSE POUR L'IMAGERIE PAR RÉSONANCE MAGNÉTIQUE MOLÉCULAIRE
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2017027834A1

  公开（公告）日：2017-02-16

  Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

  以下是具有高亲和力的金属螯合配体的示例，这些配体对锰具有高亲和力。由此产生的金属配合物可用作MRI对比剂，并且可以与结合到或在生物化学靶标存在时引起松弛度变化的基团发生功能化。
• Manganese-based chelate conjugates for molecular MR imaging
  申请人：The General Hospital Corporation

  公开号：US10835623B2

  公开（公告）日：2020-11-17

  Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

  本文提供了对锰具有高亲和力的金属螯合配体实例。由此产生的金属复合物可用作核磁共振成像造影剂，并可通过与生化靶标结合或在生化靶标存在时引起弛豫性变化的分子进行官能化。
• Compositions and methods for the treatment of irritable bowel syndrome
  申请人：CELLIX BIO PRIVATE LIMITED

  公开号：US11078154B2

  公开（公告）日：2021-08-03

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

  本文公开的化合物为式 I 或其药用盐，以及它们的多晶型物、对映体、立体异构体、溶解物和水合物。这些盐类可配制成药物组合物。这些药物组合物可配制成口服、栓剂、透皮、口腔、直肠、局部、透皮、透粘膜、静脉注射、肠外给药、糖浆或注射剂。此类组合物可用于治疗肠易激综合征（IBS）、炎症性肠病或其相关并发症。
• MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING
  申请人：The General Hospital Corporation

  公开号：US20190001003A1

  公开（公告）日：2019-01-03

  Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.